Menu
0
0

Your Cart is Empty

Conferences
  • LDN 2021
  • LDN 2022
  • LDN 2023

  • Who is the LDN Research Trust?

    In 2004, the LDN Research Trust Charity was founded in the UK, although we help people around the world. The primary aim of the Trust is to Initiate Clinical Trials of Low Dose Naltrexone for Autoimmune Diseases and Cancers.

    Whilst working to raise funds for trials, we have helped over 100,000 people to obtain LDN from a General Practitioner or Consultant, either through the National Health Service or by private prescription. We are proud to have helped people not just in the UK but in countries throughout Europe, as well as the USA, Canada, West Indies, Australia, New Zealand, and beyond. On this website and from our downloadable newsletters, you will be able to read the stories of some of these people.

    LDN 2023 CONFERENCE

    June Friday 23rd – Sunday 25th 2023
    Anthracite Hotel, Carbondale, PA USA

    FIND OUT MORE
    2023 Medical Membership

    Our website is very busy! Google Analytics stats for 2020- 2.2 million visits, 42% look at the prescriber and pharmacy pages.

    FIND OUT MORE
    LDN Books FIND OUT MORE
    The LDN Masterclass

    • Online Course
    • for MDs, NDs, NPs, Pharmacist, Nurses and
    • Other Medical Professionals
    • Online Exam, pass mark 95%
    • LDN Specialist Certificates awarded to Prescribers, Pharmacists and Other Medical Professiponals
    • Pass course exam annually to remain certified

    FIND OUT MORE
    Webinars and Training Courses FIND OUT MORE

    Subscribe.

    * indicates required
    Select a Mailing List - you must be 16+ *

    LDN Research Trust will use the information on this form to email you. Tick the box/boxes below.

    You can unsubscribe at any time by clicking link in the footer of any emails, or email contact@ldnresearchtrust.org. We treat your information with respect. Our privacy policy is on our website. By clicking submit, you agree we can process your information in accordance with those terms.

    We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.